Zoetis (ZTS) is set to release its quarterly earnings on Thursday, with expectations of growth. A Q2 2025 dividend has been announced for shareholders and the company's balance sheet is notably healthy. Various investment management firms such as Appleton Partners Inc. MA, Financial Advocates Investment Management, and Bleakley Financial Group LLC have changed their stock positions in Zoetis. The firm receives an average 'Buy' rating from brokerages. Librela label update and market potential are seen as positive factors for the company's outlook. Various predictions are made for Zoetis' Q1 earnings. Stakeholders have significant expectations for the company to beat estimates again in its next earnings report. Despite some pessimistic forecasts for the company's stock price, Zoetis continues to deliver a better return on equity than its industry. The firm's dividend is increased by 16% to a record $0.50, demonstrating a strong financial performance. Despite a recorded 18% loss for investors over the last three years, Zoetis is still seen as a profitable pharmaceutical stock and a smart investment in the sector.
Zoetis ZTS News Analytics from Mon, 04 Nov 2024 08:00:00 GMT to Sat, 08 Feb 2025 11:15:48 GMT -
Rating 8
- Innovation 2
- Information 7
- Rumor -4
